SinoMab BioScience Ltd., a Hong Kong-based biopharmaceutical company, has announced the issuance of 112,810,817 new shares under a general mandate. The shares will be issued at a subscription price of HK$1.10 per share. This move is part of a subscription agreement between SinoMab and twenty-six subscribers. The initiative aims to raise capital by leveraging the general mandate, which allows the company to issue new shares up to 20% of its existing issued shares. The announcement was made by the company's Executive Director, Chairman, and CEO, Dr. Shui On Leung.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。